Clinical trial
Iressa Expanded Access Program (EAP)
NCT00034879 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00034879 |
|---|---|
| Title | Iressa Expanded Access Program (EAP) |
| Official title | An Expanded Access Clinical Program With ZD1839 (IRESSA®) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-small-cell Lung, Metastases, Neoplasm |
| Intervention type | Drug |
| Interventions | ZD1839 (Gefitinib) |
| Start date | Aug 1, 2000 |
| Primary completion | Oct 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | May 3, 2002 |
| Last update posted | Jan 4, 2013 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: